Tulisokibart for Non-Infectious Uveitis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial will help researchers learn if tulisokibart, the trial medicine, can treat non-infectious intermediate, posterior, or panuveitis (NIIPPU) so that steroids can be given for a shorter period of time. In this trial, researchers will look at different doses (amounts) of tulisokibart.
The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until NIIPPU gets worse. A placebo looks like the trial medicine but has no medicine in it. Using a placebo helps researchers better understand the effects of the trial medicine.
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for people with active, non-infectious uveitis (inflammation in the middle or back part of the eye) in at least one eye. Participants must be on stable doses of allowed immune-suppressing medicines and steroids before joining.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Tulisokibart
Trial Overview
The study compares different doses of tulisokibart to a placebo, both given along with standard steroid treatment (prednisone), to see if tulisokibart can help control uveitis so that steroids can be used for a shorter time.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Participants receive background therapy of prednisone plus a high dose of tulisokibart.
Participants receive background therapy of prednisone plus a low dose of tulisokibart.
Participants receive background therapy of prednisone plus placebo to tulisokibart.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.